Charles River (CRL) Director Nancy Andrews Exercises Options, Sells 573 Shares

What Happened

• Nancy C. Andrews, a director of Charles River Laboratories (CRL), exercised options to acquire 573 shares on Aug 18, 2026 at $164.30 per share (total cost $94,144) and sold those 573 shares the same day in an open-market transaction at $285.24 per share (gross proceeds $163,443). The filing also reports the conversion/disposition of the related derivative (573 units at $0.00), which reflects the option being converted/cancelled on exercise.
• This is effectively a cashless exercise followed by an immediate sale — a routine liquidity event rather than an outright buy (not a bullish purchase).

Key Details

• Transaction date: Aug 18, 2026; Filing date: Aug 20, 2026.
• Exercise: 573 shares at $164.30 each (total $94,144).
• Sale: 573 shares at $285.24 each (total proceeds $163,443).
• Derivative conversion: 573 units reported disposed at $0.00 (reflects cancellation/conversion of the option on exercise).
• Shares owned after transaction: not specified in this filing.
• No 10b5-1 plan, tax-withholding, or late-filing flag stated in the provided data.

Context

• When an insider exercises options and immediately sells the resulting shares, it is commonly a cashless exercise to cover the exercise cost and taxes; it does not necessarily signal a change in the director’s view of the company. The filing documents both the option exercise (M) and the open-market sale (S), plus the derivative conversion tied to the exercise.